H.C. Wainwright Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)

July 31, 2026 6:42 AM

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $620.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found